DUBLIN – Shares in Tigenix NV gained 23 percent Tuesday on news of a sizeable ex-U.S. deal with Takeda Pharmaceutical Co. Ltd. for its allogeneic cell therapy for Crohn's disease, Cx601, which is currently undergoing regulatory review in Europe.

DUBLIN – Leo Pharma A/S is putting biologic therapies at the heart of its strategy by making two big bets in a dermatology alliance with Astrazeneca plc under which it will take on development of tralokinumab, an interleukin-13 (IL-13) inhibitor, in atopic dermatitis, and the troubled IL-17 receptor inhibitor brodalumab in plaque psoriasis.

DUBLIN – Shares in Celyad SA fell 40 percent in Brussels Tuesday on news that its C-Cure stem cell therapy failed to reach the primary endpoint of a phase III trial in patients with congestive heart failure.

DUBLIN – Shares in GW Pharmaceuticals plc rose as much as 28 percent Monday on news that Epidiolex, its liquid formulation of plant-derived cannabidiol, hit the primary endpoint of a phase III trial in patients with Lennox-Gastaut syndrome (LGS), a rare and difficult-to-treat form of childhood-onset epilepsy.

DUBLIN – Biotech investors shrugged off short-term fears about any potential fallout from Thursday's looming vote on Britain's continued membership of the EU, pumping more than $125 million into two U.K. firms, Verona Pharma plc and F2G Ltd., which will enable them to move their respective drug candidates into a phase IIb trial in chronic obstructive pulmonary disease (COPD) and a registration study in invasive aspergillosis.

DUBLIN – Shares in Scancell Holdings plc fell over 16 percent Friday on news that the company had to bin supplies of its candidate DNA-based cancer vaccine SCIB1, as routine testing showed the clinical material no longer conformed to its original specification.

DUBLIN – Fourteen exits in the last three years enabled Gilde Healthcare to close out rapidly its fourth fund, Gilde Healthcare IV, at €250 million (US$282 million). That mark represented its hard cap or upper limit – it had sought €200 million initially.

DUBLIN – Uniqure NV and Spark Therapeutics Inc. presented heavily trialed data on their respective gene therapy programs in hemophilia B at the European Hematology Association (EHA) meeting in Copenhagen, Denmark, Saturday.

Bone Therapeutics SA's autologous osteoblastic cell therapy for osteonecrosis of the hip hit the primary endpoint of a phase IIb trial, with one single treatment sufficient to slash fracture rates in two and to induce clinical responses that lasted up to three years.